In TRACERx tumor tissues (Fig. 3c), we observed evidence for methylation-dependent dosage compensation in LRRC34 when co-amplified with the PI3KCA oncogene in both tumor PDCs (Supplementary Table 7). This evidence concerns the gene LRRC34 and neoplasm.